Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Overview
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Companies Involved in Therapeutics Development
Adlai Nortye Biopharma Co Ltd
AstraZeneca Plc
Bayer AG
Chia Tai Tianqing Pharmaceutical Group Co Ltd.
Curis Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Karus Therapeutics Ltd
Novartis AG
PIQUR Therapeutics AG
SiglRx Pharmaceuticals Inc
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Drug Profiles
BAY-1082439 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bimiralisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buparlisib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fimepinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2636771 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KA-2237 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MIPS-9922 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PQR-514 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-2523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PI3K for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pan PI3K for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PI3K Beta for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PIK3CB and PIK3CD for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WX-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Dormant Products
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Discontinued Products
Phosphatidylinositol 4,5 Bisphosphate 3 Kise Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kise 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Product Development Milestones
Featured News & Press Releases
Appendix



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Bayer AG, H1 2020
Pipeline by Chia Tai Tianqing Pharmaceutical Group Co Ltd., H1 2020
Pipeline by Curis Inc, H1 2020
Pipeline by Gilead Sciences Inc, H1 2020
Pipeline by GlaxoSmithKline Plc, H1 2020
Pipeline by Karus Therapeutics Ltd, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by PIQUR Therapeutics AG, H1 2020
Pipeline by SignalRx Pharmaceuticals Inc, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020